Ptc Therapeutics (PTCT) Non-Current Debt (2016 - 2025)
Historic Non-Current Debt for Ptc Therapeutics (PTCT) over the last 12 years, with Q2 2025 value amounting to $286.0 million.
- Ptc Therapeutics' Non-Current Debt rose 42.38% to $286.0 million in Q2 2025 from the same period last year, while for Jun 2025 it was $286.0 million, marking a year-over-year increase of 42.38%. This contributed to the annual value of $285.4 million for FY2024, which is 42.19% up from last year.
- As of Q2 2025, Ptc Therapeutics' Non-Current Debt stood at $286.0 million, which was up 42.38% from $285.7 million recorded in Q1 2025.
- In the past 5 years, Ptc Therapeutics' Non-Current Debt registered a high of $573.2 million during Q3 2023, and its lowest value of $281.6 million during Q3 2021.
- Over the past 5 years, Ptc Therapeutics' median Non-Current Debt value was $285.3 million (recorded in 2024), while the average stood at $364.3 million.
- Its Non-Current Debt has fluctuated over the past 5 years, first surged by 10281.45% in 2022, then plummeted by 5028.83% in 2023.
- Quarter analysis of 5 years shows Ptc Therapeutics' Non-Current Debt stood at $281.9 million in 2021, then soared by 102.81% to $571.7 million in 2022, then plummeted by 50.29% to $284.2 million in 2023, then increased by 0.42% to $285.4 million in 2024, then increased by 0.21% to $286.0 million in 2025.
- Its Non-Current Debt was $286.0 million in Q2 2025, compared to $285.7 million in Q1 2025 and $285.4 million in Q4 2024.